Aphton Presented Phase III Data for Monotherapy with G17DT for Advanced Pancreatic Cancer Patients to Overseas Regulatory Agency.
Business Wire › March 04, 2003
Linked as:
Extract
Aphton Presented Phase III Data for Monotherapy with G17DT for Advanced Pancreatic Cancer Patients to Overseas Regulatory Agency.
Business Editors/Health/Medical Writers
BIOWIRE2K MIAMI--(BUSINESS WIRE)--March 4, 2003 Prepares for Filing for Approval to Market in the EU, Canada And Australia Aphton Corporation (Nasdaq:APHT) a...See the full content of this document
Sponsored links
